Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q4 FY2025 Earnings Presentation
43 slides from Jubilant Ingrevia's earnings presentation, May 13, 2025
Slide 1: Cover letter to BSE and NSE
May 13, 2025 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Press Release and presentation on the financials and operat
Slide 2: Jubilant Ingrevia Limited – Q4 & FY25 Results
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Tuesday, May 13th, 2025 JUBILANT INGREVIA LIMITED – Q4 & FY25 RESULTS 1 Particulars Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Total Revenue 1,074 1,057 1,051
Slide 3: Q4'FY25 Highlights | Segment Wise Analysis – Specialty Chemicals
Business Update: In the Specialty Chemicals Business segment, overall volumes remained stable. We are observing continuous growth momentum across our Pyridine & Picoline, Fine Chemicals and CDMO businesses, with an expanded pipeline of newer opportunities for coming quarters. In certain segments, we
Slide 4: B. Nutrition & Health Solutions
Agrochemical - With volumes gradually coming back, witnessed YoY volumes growth, while pricing remained stable. - Inventory destocking seems to be tapering off CDMO - Substantial increase in volumes both QoQ and YoY, fueled by a rising number of inbound inquiries from the Agro, Pharma, and Semicondu
Slide 5: C. Chemical Intermediates Segment
C. Chemical Intermediates Segment Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Segment Revenue 435 400 375 -6% -14% 1,870 1,612 -14% % Share of Overall Revenue 40% 38% 36% 45% 39% EBITDA 43 22 10 -53% -76% 202 108 -47% % EBITDA Margin 10% 5% 3% 11% 7% 2 % Contribution to EBITDA 3
Slide 6: Income Statement and Segment P&L – Q4'FY25
3. Income Statement – Q4’FY25 Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 QoQ YoY FY24 FY25 YoY Revenue from operations a) Sales/Income from operations 1060 1046 1038 -1% -2% 4100 4124 1% b) Other operating income 14 11 13 22% -8% 35 54 53% Total revenue from operations 1074 1057 1051 -1% -2% 4136 4178 1%
Slide 7: Debt Position as on 31st March 2025
5. Debt Position as on 31st December, 2024 Particulars1 31-Mar-24 31-Dec-24 31-Mar-25 Long Term Borrowings 450 457 396 Short Term Borrowings 283 291 360 Total Gross Debt 733 748 756 Cash & Equivalent 80 67 98 Total Net Debt 653 681 658 YoY change 1% All figures are in Rs Crore unless otherwise state
Slide 8: For more information, please contact
For more information, please contact: For Investors Pavleen Taneja Siddharth Rangnekar Jubilant Ingrevia Limited CDR India Ph: +91-120 436 1000 Ph: +91 22 6645 1209 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media Sandipan Ghatak Ryan Marshall Ph: +91-120 436 1062 M: +91 981
Slide 9: Investor Presentation
Jubilant Ingrevia Limited Investor Presentation May 2025 Environment Social Governance O2 contract – Sourcing 35% of total energy through renewables S&P DJSI – Obtained 92 percentile in Global Chemical Industries EcoVadis – Achieved Gold rating with Top 95 percentile 1
Slide 10: Forward-looking statements
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 11: Management commentary and dividend declaration
“We are pleased to announce the sustained growth in revenue and margins for our Specialty Chemicals and Nutrition businesses. Our ongoing cost reduction efforts have further boosted our profitability, with quarter’s EBITDA margin reaching 14.7% and Profit After Tax increasing by 153% on YoY basis. D
Slide 12: Business Update
Business Update: In the Specialty Chemicals Business segment, overall volumes remained stable. We are observing continuous growth momentum across our Pyridine & Picoline, Fine Chemicals and CDMO businesses, with an expanded pipeline of newer opportunities for coming quarters. In certain segments, we
Slide 13: Table of Contents
Table of Contents 0 6 Company Overview 1 3 Growth Roadmap 1 9 Q4’FY25 Highlights 2 6 Business Segments Update 5
Slide 14: Company Overview
Company Overview . Visuals of our New Diketene Derivatives Plant in Gajraula 6
Slide 15: Transformation into Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine • Started as VAM • Forward integration into • Foray into Pyridine derivatives Organics Pyridine derivatives Chemistry • Foray into Dike
Slide 16: Business segments and product leadership
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 17: Revenue mix by segment, end-use and geography
Consumer 4% ROW Nutrition North 9% & Health Agro America Solutions 19% Pharma 9% 18% SpecialtyC 32% India hemicals4 53% 4% Europe & Japan Chemical Industrial 29% Intermediates 24% 39% Nutrition 21% 9
Slide 18: Manufacturing sites and operational capabilities
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 19: R&D Centers
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 150 26 R&D Centers Scientists PhDs 11
Slide 20: Business and Function Leaders
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola Chief Financial Officer
Slide 21: Growth Roadmap (Recap)
J UBIIANT INGREVIA Growth Roadmap (Recap)
Slide 22: Purpose, Vision and Values
PURPOSE VISION Enable a Sustainable World through Chemistry Leading provider of innovative solutions in our core chemistries globally World-class, Customer Innovation & People Safe Operations ESG Leader CAPABILITIES/ Centricity Technology Focused CORE PILLARS Inspire Challenge Innovate Excel Collabo
Slide 23: Pinnacle 3.4.5 growth ambition
We set out on an ambitious growth path — Pinnacle 345 pean INGREVIA ~PINNACLE»3.4.5 — uv@ oe times | times Ii. year ail REVENUE EBITDA HORIZON
Slide 24: Today vs Tomorrow transformation
Today Past Tomorrow Future Portfolio High dependence on commoditized chemicals Higher focus on Specialty chemicals (downstream value-added products, CDMO) Mindset Primarily product / manufacturing first mindset “Customer-centric” approach R&D focus Focus on incremental innovation of existing product
Slide 25: Pinnacle 3.4.5 Growth Pillars
PINNACLE3.4.5 PINNACLE 3.4.5 G R O W T H P I L L A R S New Growth Areas A Specialty Chemicals B Nutrition & Health solutions C Chemical Intermediates Pyridine & Picoline Retain Global leadership (#1 position, cost leadership) Animal Nutrition Acetic Anhydride Scale up Oilfield chemicals Feed Vit B3:
Slide 26: Key milestones and achievements
WEF Lighthouse award at Davos 120 Cr+ of Lean/Surge/BE Investor day in initiatives Turnaround in Commissioning of Mumbai (28th Feb) Europe/US/ Japan DIKETENE Derivatives roadshows - 100+ Specialty and Cosmetic Grade Nutrition with Niacinamide plant Ecovadis and DJSI plants customers increase in EBIT
Slide 27: Q4 & FY25 Highlights
Q4 & FY25 Highlights 19 19
Slide 28: Pharma, Agrochem and Nutrition market update
PHARMA • Consistent volume demand across segments, especially in our Fine Chemicals portfolio • Prices remain stable across various segments, with certain areas seeing an increase. • Demand for paracetamol end-use remains subdued as customers run their plants below optimal capacity. AGROCHEM • Globa
Slide 29: Core product platforms continue to drive growth and leadership
• Pyridine & Picoline: Globally #1 position in P&P (only scaled non-Chinese player), Significant volume Core product platforms continue to growth in FY25; Prices moved up in select segments drive growth and leadership; Acetyls • Niacinamide: Maintained leadership position (Top 2) in feed grade with
Slide 30: Revenue & EBITDA drivers during the quarter
Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Total Revenue 1,074 1,057 1,051 -1% -2% 4,136 4,178 1% Total EBITDA 101 148 155 5% 54% 456 557 22% EBITDA Margin (%) 9% 14% 15% 11% 13% Profit After Tax 29 69 74 7% 153% 183 251 37% Profit After Tax Margin (%) 3% 7% 7% 4% 6% Basic and
Slide 31: Strong EBITDA growth despite pressure on acetyl business
Despite the pressure on acetyl business, we continue to see strong EBITDA growth 20.0% 180 EBITDA (INR Crs.) EBITDA Margins 155 160 18.0% 148 Highest EBITDA 135 Margin140 in last 12 16.0% 125 126 quarters 119 14.7% 14.0% 120 14.0% 104 101 12.9% 100 12.1% 12.0% 11.6% 11.6% 10.8% 80 10.0% 9.4% 60 8.0%
Slide 32: Segment-wise EBITDA Share (%)
Segment-wise EBITDA Share (%) 6% 13% 25% 27% 17% 36% 36% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Specialty Chemicals Nutrition & Health Chemical Intermediates 24
Slide 33: Specialty Chemicals and Nutrition & Health Solutions EBITDA
Specialty Chemicals Nutrition & Health Solutions EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 93% Y.o.Y Growth 237% Q.o.Q Growth 7% Q.o.Q Growth 17% 129 121 29 25 67 9 14% 26% 27% 5% 13% 16% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Notable increase in the volumes and prices in Pyridine Qo
Slide 34: Business Segments Overview
Business Segments Overview 26
Slide 35: Specialty Chemicals: Pharma, Agrochemical, CDMO
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Steady demand growth from the end-use segment maintained strong volumes, while Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y prices remained stable with increases in Segment Revenue 475 468 487 4% 2% 1,585.5 1,818 15% Pharma certain segment
Slide 36: Nutrition & Health Solutions: Feed B3, Choline
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS 1 Particulars Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Increased sales volume on YoY basis. Segment Revenue 165 190 190 0% 15% 680 747 10% Niacinamide pricing improved on YoY basis % Share of Overall Revenue Feed B3 15% 18% 18% 16% 18% EBITDA 9 25
Slide 37: Chemical Intermediates: Volumes, Cost, Price
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Acetic Anhydride is still encountering challenges from its main end-use markets, e.g. Paracetamol Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Greater emphasis on Ethyl Acetate volumes Segment Revenue 435 400 375 -6% -14% 1,870 1,612 -14%
Slide 38: Annexures
J Ww JUBHANT Increvia 1 Breve fA
Slide 39: Income Statement
1 Particulars Q4'FY24 Q3'FY25 Q4'FY25 QoQ YoY FY24 FY25 YoY Revenue from operations a) Sales/Income from operations 1060 1046 1038 -1% -2% 4100 4124 1% b) Other operating income 14 11 13 22% -8% 35 54 53% Total revenue from operations 1074 1057 1051 -1% -2% 4136 4178 1% Other income 10 9 8 -11% -12%
Slide 40: Segment Revenue, EBITDA and Margins
Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 QoQ (%) YoY (%) FY24 FY25 YoY (%) Revenue Speciality Chemicals 475 468 487 4% 2% 1,586 1,818 15% Nutrition & Health Solutions 165 190 190 0% 15% 680 747 10% Chemical Intermediates 435 400 375 (6%) (14%) 1,870 1,612 (14%) Total Revenue from Operations 1,074 1,057
Slide 41: Debt Position
Particulars1 31-Mar-24 31-Dec-24 31-Mar-25 Long Term Borrowings 450 457 396 Short Term Borrowings 283 291 360 Total Gross Debt 733 748 756 Cash & Equivalent 80 67 98 Total Net Debt 653 681 658 YoY change 1% • The capex for the quarter was Rs 65 Crore and YTD was Rs 365 Crore, which was primarily fun
Slide 42: Earnings Call Details
Diamond Pass Log-In Date : May 13th, 2025 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on the re
Slide 43: Thank you for your time
Jubilant Ingrevia Limited is a globally integrated Life Sciences & For Investors: Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad Pavleen Taneja portfolio of over 130+ products and customized solutions that are Jubilant